# NCT02537548 (NCT02537548)

> Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma

No report yet. It can be ordered.

- Drugs tested: none (the trial tests no drug)
- Indication: testicular seminoma with limited retroperitoneal lymphadenopathy

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02537548
- Phase: NA
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: University of Southern California
- Conditions: Lymphadenopathy; Stage I Testicular Seminoma; Stage II Testicular Seminoma
- Interventions: Laboratory Biomarker Analysis; Retroperitoneal Lymph Node Dissection
- Enrollment: 55
- Primary outcome: RFS

## Questions raised in the commentary

_Automated from all 33 indexed sources (Nov 2018 – Sep 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether results apply beyond highly selected, low-volume disease
- Whether longer follow-up changes estimates of recurrence risk
- How RPLND compares with chemotherapy or radiotherapy

Also discussed: PET for nodal assessment, salvage treatment after relapse, long-term treatment toxicity.

## Indexed commentary on NCT02537548 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 27
- Podcasts: 4
- YouTube: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct02537548

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02537548", "email": "<work email>"}; the inbox owner confirms by the emailed link.